Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Division is delighted to welcome Dr Anjan Thakurta to Oxford, having now taken up his position of Visiting Professor of Cancer, Biology and Translational Science within the Radcliffe Department of Medicine.

None

Dr Thakurta will provide strategic support and advice to the Medical Sciences Division and foster new collaborations between the University of Oxford and Celgene. He will also facilitate greater access to and opportunities with senior Celgene scientists for University of Oxford researchers, enabling them to gain a deeper understanding of the scope and potential of Celgene’s portfolio of work and an industry perspective on research questions. Whilst in Oxford, Dr Thakurta will be based in the MRC Weatherall Institute of Molecular Medicine (MRC WIMM).

Dr Thakurta brings extensive knowledge of Celgene’s early therapeutic pipeline and translational biology programmes, especially in haematology / oncology, and over 20 years’ experience in translational and clinical drug development. Most recently, leading the myeloma disease team, one of Celgene’s major disease areas. Prior to this, he led translational and diagnostic work across all haematological areas in Celgene.

Dr Thakurta brings with him a wealth of experience in mentoring scientists in the early stages of their careers, and has previously supervised Oxford-Celgene fellows.  His advice on Oxford-Celgene Fellowship Programme applications will not only support the development of cutting-edge science, but also the training of the next generation of scientists and clinical academics.

 

As Visiting Professor, I will visit Oxford regularly, interact with current and potential future fellows and look forward to establishing some new and exciting collaborations and translational initiatives at the university over the next three years. - Dr Anjan Thakurta, Celgene

 

I am really pleased Dr Thakurta has been awarded the position of Visiting Professorship and has taken this up position. Dr Thakurta has a wealth of experience in drug development especially in haematological disease and has already mentored two young aspiring clinical academics, who have successfully started their independent careers in Oxford. He has also made important links with a number of Oxford groups and I am sure these new relationships will be enormously productive, helping to transform patient care as well as providing wonderful academic opportunities for Oxford University, Oxford University Hospitals NHS Foundation Trust and Celgene - Professor Paresh Vyas, Professor of Haematology, MRC Molecular Haematology Unit, MRC WIMM, University of Oxford

 

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.